Gene Therapy Bioassays Market Report 2026

Gene Therapy Bioassays Market Overview

• Gene Therapy Bioassays market size has reached to $1.21 billion in 2025 • Expected to grow to $2.62 billion in 2030 at a compound annual growth rate (CAGR) of 16.7% • Growth Driver: Increase In Gene Therapy Clinical Trials Is Fueling The Growth Of The Market Due To Rising Demand For Analytical Testing To Ensure Safety, Potency, And Efficacy Across Clinical Development Stages • Market Trend: Integrating Artificial Intelligence For Enhanced Accuracy And Efficiency In Gene Therapy Bioassay Analysis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gene Therapy Bioassays Market?

Gene therapy bioassays refer to laboratory tests used to evaluate the biological activity, potency, and functional performance of gene therapy products, ensuring the therapeutic gene or vector works as intended. They are essential for assessing Gene Expression, vector efficiency, and safety to support product development, quality control, and regulatory approval. The main product types of gene therapy bioassays include cell-based assays, viral vector-based assays, non-viral vector-based assays, and other product types. Cell-based assays refer to tests that use living cells to evaluate the efficacy, potency, and safety of gene therapy products in a controlled laboratory environment. These bioassays are offered as services including assay development services, assay validation services, quality control testing services, regulatory support services, data analysis and reporting services, and custom bioassay design services. They are applied across areas including research and development, clinical testing, quality control, and other applications, and are used by end users including biotechnology companies, pharmaceutical companies, contract research organizations, academic and research institutes, and regulatory laboratories.

What Is The Gene Therapy Bioassays Market Growth Forecast?

The gene therapy bioassays market size is expected to see rapid growth in the next few years. It will grow to $2.62 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to increasing commercialization of gene therapies, rising demand for high-throughput bioassay solutions, expansion of personalized genetic medicine, growing investments in advanced cell and gene therapy pipelines, increasing focus on assay automation and reproducibility. Major trends in the forecast period include increasing adoption of cell-based potency assays, rising demand for viral vector characterization tests, growing use of automated bioassay platforms, expansion of regulatory-compliant assay validation, enhanced focus on functional gene expression analysis.

Global Gene Therapy Bioassays Market Segmentation

1) By Product Type: Cell-Based Assays; Viral Vector-Based Assays; Non-Viral Vector-Based Assays; Other Product Types 2) By Service Type: Assay Development Services; Assay Validation Services; Quality Control Testing Services; Regulatory Support Services; Data Analysis And Reporting Services; Custom Bioassay Design Services 3) By Application: Research And Development; Clinical Testing; Quality Control; Other Applications 4) By End User: Biotechnology Companies; Pharmaceutical Companies; Contract Research Organizations; Academic And Research Institutes; Regulatory Laboratories Subsegments: 1) By Cell-Based Assays: Reporter Gene Expression Assays; Cell Viability And Cytotoxicity Assays; Transduction Efficiency Assays; Functional Potency Cell Assays; Cellular Uptake And Localization Assays 2) By Viral Vector-Based Assays: Adeno Associated Virus Vector Assays; Lentiviral Vector Characterization Assays; Retroviral Vector Titer Assays; Vector Genome Integrity Assays; Infectivity And Transduction Assays 3) By Non-Viral Vector-Based Assays: Plasmid Deoxyribonucleic Acid Delivery Assays; Lipid Nanoparticle Transfection Assays; Polymeric Carrier Efficiency Assays; Physical Gene Delivery Evaluation Assays; Non Viral Vector Stability Assays 4) By Other Product Types: Immunogenicity Assessment Assays; Biodistribution And Persistence Assays; Safety And Toxicity Bioassays; Analytical Method Development Assays; Custom Gene Therapy Bioassays

What Is The Driver Of The Gene Therapy Bioassays Market?

The increasing number of gene therapy clinical trials is expected to drive growth in the gene therapy bioassays market. Gene therapy clinical trials evaluate the safety, efficacy, and biological performance of gene-based treatments in human subjects. The expansion of these trials is driven by intensified research and development efforts and growing investment from biopharmaceutical companies seeking to address unmet medical needs through innovative genetic therapies. Gene therapy bioassays support clinical development by providing critical analytical tests to assess biological activity, potency, safety, and mechanism of action at each stage of development, with regulatory requirements increasing as programs advance through clinical phases. For instance, in January 2026, according to Bioindustry Association (BIA), a UK-based national trade association, the UK had 193 ongoing advanced therapy clinical trials, over 80% of which were focused on gene therapies. Therefore, the surge in gene therapy clinical trials is driving the growth of the gene therapy bioassays industry.

Key Players In The Global Gene Therapy Bioassays Market

Major companies operating in the gene therapy bioassays market are Boehringer Ingelheim BioXcellence, AGC Biologics, ICON plc, Lonza Group AG, SGS SA, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc., Catalent Inc, Recipharm AB, KBI Biopharma, Syngene International Limited, QPS Holdings LLC, BioAgilytix Labs (operationally independent CRO), Oxford Biomedica plc, Viralgen Vector S.L., ProtaGene Inc., Center for Breakthrough Medicines, RoslinCT, Immunologix Labs, Genezen Laboratories

Global Gene Therapy Bioassays Market Trends and Insights

Major companies operating in the gene therapy bioassays market are focusing on the integration of artificial intelligence and machine learning in bioassay analysis, such as AI-enabled digital PCR data interpretation, to enhance accuracy, reduce experimental variability, accelerate result turnaround, and optimize the assessment of therapeutic efficacy and safety in gene therapy development. AI-enabled dPCR data interpretation uses advanced algorithms to automate result analysis, distinguish true signals from background noise, and accurately quantify viral genomes or vector copy number with minimal human intervention. For instance, in April 2025, QIAGEN N.V., a Germany-based molecular diagnostics company, launched expanded QIAcuity lentivirus solutions, including the QIAcuity RCL Quant Kit and CGT dPCR assays. These solutions feature algorithm-driven absolute quantification, multiplex and singleplex assay compatibility for vector genome and vector copy number analysis, and software-assisted data analysis workflows designed to support regulatory-compliant decision-making in gene therapy bioassay applications.

What Are Latest Mergers And Acquisitions In The Gene Therapy Bioassays Market?

In April 2025, Artis BioSolutions LLC, a US‑based cell and gene therapy contract development and manufacturing company, acquired Landmark Bio, for an undisclosed amount. With this acquisition, Artis BioSolutions aims to expand its service portfolio and strengthen its end‑to‑end capabilities across gene therapy production, including advanced manufacturing and analytical support increasingly demanded by biopharmaceutical firms in the gene therapy and bioassay market. Landmark Bio PBLLC is a US‑based contract development and manufacturing organization (CDMO) that provides gene therapy bioassays, offering analytical and QC testing to support the safety, potency, and efficacy assessment of cell and gene therapy products.

Regional Insights

North America was the largest region in the gene therapy bioassays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gene Therapy Bioassays Market?

The gene therapy bioassays market consists of sales of viral vector titer quantification reagents, reporter bioassay systems, nucleic acid purification systems, cell lines and assay-ready cells, and potency assay reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gene Therapy Bioassays Market Report 2026?

The gene therapy bioassays market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy bioassays industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.